Follow us:

For Investors

 

 

Highlights:

  • InspireMD addresses a growing, $1.8B market
  • Target market has limited competition
  • Aging population and desire for less invasive therapies create favorable growth demographics

 

InspireMD to host a conference call at 4:30 p.m. ET on Wednesday, November 12th to review its financial results and business outlook.

 

http://public.viavid.com/index.php?id=111868

U.S. Dial-in:  (877) 407-0784

International Dial-in: (201) 689-8560

 

Recently Released Results of CGuard™ CARENET Trial on September 24th

Click Link below

http://public.viavid.com/player/index.php?id=111009

U.S. Dial-in: (877) 407-0789

International Dial-in: (201) 689-8562

 

Summary:

InspireMD Ltd. is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™.

 

InspireMD has created a unique, patent-pending mesh net technology that wraps a stent, providing embolic protection (preventing Major Adverse Cardiac Events (MACE) by filtering debris) and reducing vessel injury by spreading strut pressure. MGuard™ is delivered with no change to the current procedure and is well-accepted by physicians. MGuard™ has been implanted in thousands of patients, and in clinical trials it has shown a more than 50% reduction in MACE compared with traditional bare metal stents.

ASTUDIO | Design & Development